BioSpace News Archive

AstraZeneca and MedImmune, its global biologics research and development arm presented results from the Phase III (‘1053’) clinical trial (Abstract #7004) that evaluated moxetumomab pasudotox in 80 patients with relapsed or refractory hairy cell leukemia (HCL) who had received at least two prior lines of therapy.

NantOmics, LLC will present findings on how pazopanib (PZ) has meaningful clinical activity in patients with progressive desmoid tumors (DT) during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

NantHealth, Inc., and NantOmics, LLC will present findings on how targeting immune checkpoints and employing combinations has led to clinical benefit across a variety of tumor types during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

NantHealth, Inc. unveiled Liquid GPS™ a powerful next-generation tool for blood-based tumor profiling and quantitative monitoring.

This week, justice and recovery professionals fighting the nation’s battle against the opioid epidemic have convened in Houston for the National Association of Drug Court Professionals (NADCP) annual conference.

NantOmics, LLC will present findings on potential treatment options for small-cell lung cancer (SCLC) patients with multiplexed clinical proteomic testing during the lung cancer.

NantHealth, Inc. and and NantOmics, will present data on next-generation sequencing of paired DNA and RNA analysis in patients with rare and ultra-rare cancers during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.